The other possibilty is based on this statment..... "There is potential for Valeant to find another partner for the Mesoblast assets
given the favourable clinical data to date, particularly in heart failure. we understand that Valeant sold most of the R&D programs acquired with its
Biovail7 acquisition to other natural partners" My belief is they will not pass off the MSB applications if they really understand the potential of them and future ones for that matter .But its wait and see. All conditions and payments are locked in anyway, Another plus for the MSB board on closing loopholes in all their transactions. Cheers Vin
selling, page-17
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |